Related Experiment Videos
Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis
Abstract:
Low dose pulse MTX was associated with the development of pancytopenia in six patients with RA. Two patients died. Factors implicated in the occurrence of this complication were renal impairment in five patients, medication errors by two patients, preexisting marrow injury from occult alcoholism in one patient, and an apparent idiosyncratic reaction to the drug in another. Medication errors were associated with the use of five or more medications, and the unusual schedule of administration of low dose MTX may also have been contributory. From a consideration of the clinical pharmacokinetics of MTX, we suggest other factors that may predispose to the occurrence of marrow toxicity: the presence of hypoalbuminemia, interactions between MTX and other protein bound or weakly acidic drugs, and the repetitive dosing schedule of low dose MTX. Based on our experience, patients with impaired renal function (creatinine greater than or equal to 2.0 mg/dL) should not receive MTX. Renal function should be monitored regularly during treatment with MTX, and blood counts should be observed carefully if a new drug is added or substituted. A 5 mg test dose of MTX before initiating weekly therapy may identify patients with severe hypersensitivity to the drug. The potential risks of using MTX in a patient unwilling to accept blood products should be acknowledged and discussed with the patient. Furthermore, we recommend the use of leucovorin if pancytopenia occurs, even if low or undetectable serum levels of MTX are present.
Insights
Low dose methotrexate (MTX) can cause pancytopenia in rheumatoid arthritis (RA) patients, especially with kidney issues or medication errors. Careful monitoring and dose adjustments are crucial for MTX safety.
Area of Science:
- Rheumatology
- Clinical Pharmacology
- Hematology
Background:
- Low dose pulse methotrexate (MTX) is a common treatment for rheumatoid arthritis (RA).
- Pancytopenia, a serious adverse event, has been observed in RA patients treated with MTX.
- Identifying risk factors and preventive strategies is essential for safe MTX use.
Observation:
- Six RA patients developed pancytopenia while on low-dose pulse MTX.
- Contributing factors included renal impairment (5 patients), medication errors (2 patients), pre-existing marrow injury (1 patient), and idiosyncratic reaction (1 patient).
- Medication errors were linked to polypharmacy (≥5 medications) and unusual MTX dosing schedules.
Findings:
- Renal impairment (creatinine ≥ 2.0 mg/dL) is a contraindication for MTX.
- Hypoalbuminemia, drug interactions (protein-bound or acidic drugs), and repetitive low-dose MTX schedules may increase marrow toxicity risk.
- A 5 mg test dose of MTX may identify hypersensitive patients.
Implications:
- Strict monitoring of renal function and blood counts is essential during MTX therapy.
- Caution is advised when adding or substituting medications.
- Leucovorin rescue is recommended for MTX-induced pancytopenia, regardless of serum MTX levels.
- Informed consent regarding risks, especially for patients refusing blood products, is critical.